CN110205270B - Application of lactobacillus paracasei L9 for relieving constipation of cultured animals - Google Patents
Application of lactobacillus paracasei L9 for relieving constipation of cultured animals Download PDFInfo
- Publication number
- CN110205270B CN110205270B CN201910483931.4A CN201910483931A CN110205270B CN 110205270 B CN110205270 B CN 110205270B CN 201910483931 A CN201910483931 A CN 201910483931A CN 110205270 B CN110205270 B CN 110205270B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- constipation
- mice
- months
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Physiology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention provides application of lactobacillus paracasei L9 for relieving constipation of cultured animals, wherein the lactobacillus paracasei L9 is preserved in China general microbiological culture collection center in 2014 in 10-22 months with the preservation number of CGMCC NO.9800. The lactobacillus paracasei L9 is a bifidobacterium strain with stronger tolerance. The invention utilizes animal experiments to evaluate the constipation relieving effect of the strain, and experiments prove that the lactobacillus paracasei L9 and the metabolite thereof can promote the secretion of digestive enzymes and the peristalsis of intestinal tracts of human bodies, promote the digestive absorption of foods, improve the functions of intestines and stomach, and have good functions of relaxing bowel. The lactobacillus paracasei L9 is used for preparing animal feed or pet food, and researches prove that the active lactobacillus paracasei and the inactivated lactobacillus paracasei, and derivatives thereof have the effect of improving constipation of cultured animals.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to application of lactobacillus paracasei L9 for relieving constipation of cultured animals.
Background
Lactobacillus paracasei is a probiotic lactic acid bacterium which is researched more abroad in recent years, and Lactobacillus paracasei L9 is an excellent probiotic strain screened from intestinal tracts of healthy people and widely exists in traditional fermented dairy products and gastrointestinal tracts of human bodies. A large amount of data show that the lactobacillus paracasei has wide development and application prospects in the field of probiotics. Currently, the results of the study have demonstrated that lactobacillus paracasei has the following probiotic functions: (1) antibacterial effect. The report indicates that lactobacillus paracasei has inhibitory action on some pathogenic bacteria in food and intestinal tracts, and bacteriostatic substances generated by fermentation of lactobacillus paracasei have inhibitory action on gram-positive bacteria, gram-negative bacteria and various pathogenic bacteria; (2) an antioxidant effect. Research shows that bacterial suspension, cell-free extracting solution and extracellular polysaccharide of lactobacillus paracasei have strong antioxidant activity; and (3) immunoregulation effect. The lactobacillus paracasei can enhance the immune response of intestinal tracts and systems of mice and has obvious effects on the delayed type allergic reaction of cells of the mice, the proliferation capacity of splenic lymphocytes and the activity of NK cells.
Constipation is a group of symptoms mainly complained of the symptoms of reduced defecation frequency, difficult defecation or incomplete defecation, dry and hard feces, and is a clinically very common symptom. However, constipation symptoms are not only found in human populations, but also in many animals, especially domestic pets, due to unreasonable dietary structures and the like.
Disclosure of Invention
The lactobacillus paracasei L9 has stronger acid resistance and cholate resistance and has the potential of application and development. The invention aims to provide application of lactobacillus paracasei L9 for relieving constipation of cultured animals.
The purpose of the invention is realized by the following technical scheme:
the application of the lactobacillus paracasei L9 for relieving constipation of cultured animals is characterized in that the lactobacillus paracasei L9 is preserved in China general microbiological culture collection management center in 2014 within 22 months and the preservation number is CGMCC NO.9800.
Further, the lactobacillus paracasei L9 can be applied to the preparation of drugs for treating or preventing constipation, animal feeds or pet foods.
Further, the lactobacillus paracasei L9 is a live bacterium, a killed bacterium or a derivative of the strain.
Further, the object to be eaten by the animal feed or pet food is a farmed animal.
Another aspect of the invention:
the veterinary drug contains lactobacillus paracasei L9, the lactobacillus paracasei L9 is preserved in the China general microbiological culture collection center in 2014 within 10 months and 22 days, the preservation number is CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 10 3 -10 5 CFU/g。
An animal feed or pet food, which contains lactobacillus paracasei L9, wherein the lactobacillus paracasei L9 is preserved in the China general microbiological culture collection center in 2014 at 22 months 10, and the preservation number is CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 10 2 -10 4 CFU/g。
Compared with the prior art, the invention has the beneficial effects that:
the study used animal experiments to evaluate the constipation-relieving effect of the strain. Balb/c male mice are randomly divided into a blank group, a model group, a group with high and low doses of L9 live bacteria and inactivated bacteria. Model group and L9 group use compound diphenoxylate to establish a mouse constipation model, and then three groups of model mice are respectively given low and high doses (1 × 10) 4 、1×10 5 CFU/mL) of L9 viable bacteria liquid 0.1 mL/(kg.d), blank group and model group of lavage 0.1 mL/(kg.d) (by weight) of 10% of skim milk. Defecation was evaluated using an ink propulsion method. After 7 days of administration of lactobacillus paracasei L9, the first defecation time of a constipation mouse is shortened, the number and the quality of defecation grains are obviously increased, and the water content of excrement is improved; after the lactobacillus paracasei L9 is continuously perfused for 15 days, the intestinal ink propulsion rate of the constipated mice is also obviously increased. The result shows that the lactobacillus paracasei L9 has good function of relaxing bowel.
Detailed Description
Example 1 verification of Constipation relieving efficacy of L9
Materials:
balb/c male mice, 6-8 weeks old, 18-22g in body mass, SPF grade, purchased from Beijing Wintonlifa laboratory animal technology, inc. The lactobacillus paracasei L9 strain is a self-separation preservation strain in a functional dairy product key laboratory of the Chinese agricultural university.
Preparing a solution:
preparing ink: accurately weighing 100g of Arabic gum, adding 800mL of water, boiling until the solution is transparent, weighing 50g of activated carbon (powder) and adding into the solution, boiling for 3 times, adding water to a constant volume of 1000mL after the solution is cooled, storing in a refrigerator at 4 ℃, and shaking uniformly before use.
Preparation of compound diphenoxylate suspension (0.05 g/100mL and 0.025g/100 mL): compound diphenoxylate tablet, each tablet contains compound diphenoxylate 2.5mg, 20 tablets (0.05 g/100 mL) and 10 tablets (0.025 g/100 mL) are respectively taken, ground into powder by a mortar, added with water to 50mL and prepared before use.
Culturing the strain:
lactobacillus paracasei L9 strain is anaerobically cultured for 12h at 37 ℃ by using MRS liquid culture medium, centrifuged for 15min at 4 500r/min, and thallus precipitate is suspended in 10 percent skim milk to prepare bacterial suspensions with different concentrations.
Grouping and processing experimental animals:
the experimental strains were assigned 2 dose groups, blank groups and model groups. The blank group and the model group mice are filled with skim milk with the mass fraction of 10 percent of intragastric administration of 0.1 mL/(kg. D) (by the weight of the physique); lactobacillus paracasei L9 low-dose and high-dose mice are respectively gavaged by 1 multiplied by 10 6 、1×10 8 CFU/mL suspension of viable or inactivated bacteria was 0.1 mL/(kg. D) (based on body mass). Once a day, free access to food during the trial, and body mass changes were recorded for each group of mice.
Mouse defecation experiment:
after the test sample was given for 7d, each group of mice was fasted for 16h without water deprivation. The mice of the model group and 2 dose groups were gavaged with compound diphenoxylate (10 mg/kg) and the blank group was given distilled water. 2 x 10 6 、2×10 8 The CFU/mL L9 bacterial suspension and the ink are mixed in equal volume, after the compound diphenoxylate is administered for 0.5h, the blank group and the model group mice are perfused with the stomach ink in 0.1mL/kg (by a physique amount), the low and high dose groups and the control group are administered with the ink containing the tested sample in 0.1mL/kg (by a physique amount), and the animals are all fed in a single cage and normally drink water. Starting from the gastric lavage ink, recording the first grain defecation time of each animal, the number of black grains in 5h and the quality of the black grains. The collected feces were dried at 105 ℃ until the mass was constant, and the moisture content of the feces was calculated according to the formula (1).
Resolution water content (%) = (1-). Times 100% (1)
Small intestine propulsion experiment:
after 15d of the test sample, each group of mice was fasted for 16h without water deprivation. Model and 2 dose groups mice were gavaged with compound diphenoxylate (5 mg/kg) and the blank control group was given distilled water. After 0.5h of compound diphenoxylate, the low and high dose groups and the control group are respectively administered with 0.1mL/kg (measured by body constitution) of the ink containing the tested sample (the sample dose is the same as the above-mentioned defecation experiment of the mouse), and the other control group is administered with 0.1mL/kg (measured by body constitution) of gastric lavage ink. After 25min, the cervical vertebrae is taken off immediately to kill the mouse, the abdominal cavity is opened to separate mesentery, the intestinal canal with the upper end from the pylorus, the lower end to the ileocecal part is cut and placed on a tray, the small intestine is slightly pulled into a straight line, the length of the intestinal canal is measured as the total length of the small intestine, and the length from the pylorus to the front edge of ink is measured as the ink propelling length. The ink propulsion rate was calculated according to equation (2).
Ink propulsion rate (%) = × 100% (2)
Data processing:
the ink advancing rate needs to be subjected to data conversion, X = Sin-1A, wherein A is the ink advancing rate, and the result is expressed by decimal numbers. When the variance analysis is carried out, firstly, carrying out the homogeneity of variance test by using an variance analysis program, and calculating an F value after the variances are uniform, wherein the F value is less than F0.05, so that no significant difference exists among the average numbers of each experimental group; if the F value is more than or equal to F0.05 and the P value is less than or equal to 0.05, the significant difference exists among the average numbers of all groups; a rank sum t test was performed on one control group with each experimental group data.
Change of mouse body mass:
TABLE 1 Experimental mouse body Mass Change (g)
The study was performed under normal physiological conditions in mice. As can be seen from Table 1, the body weights of the mice during the test were not significantly different between the respective dose groups and the control group (P > 0.05), indicating that Lactobacillus paracasei L9 did not have a significant effect on the body weights of the mice during the test.
Effect of lactobacillus paracasei L9 on mouse stool index:
the experimental mice were orally gavaged with Lactobacillus paracasei L9 strain once a day, and the influence on the black stool discharging time of the first particles, the number of black stool discharging particles within 5h, the quality and the water content of the stool of the constipation model mice was continuously measured after 7 days, and the results are shown in Table 2. Compared with a blank group, the mice in the model group have very significant differences (P is less than 0.01) in the first defecation time, the number of defecation particles in 5h, the defecation quality and the water content of the excrement, which indicates that the constipation mice model is established.
After the mice of each dose group of lactobacillus paracasei L9 are subjected to intragastric administration for 7d, the first defecation time, the defecation quality within 5h and the defecation grain number of the mice all reach extremely obvious levels (P is less than 0.01) compared with those of a model group; the water content of the defecate of the mice in the low and high dose groups is also obviously improved compared with the water content of the model group (P is less than 0.01). And the dosage effect is shown, and with the increase of the intragastric administration dosage, the first defecation time of the mouse, the number of defecation particles in 5h, the defecation quality, the excrement water content and other indexes are gradually enhanced.
TABLE 2 influence of the test strains on the defecation index of the constipation model mice
Note: # very significant difference (P < 0.01) compared to blank group; * There was a very significant difference compared to the model group (P < 0.01); * Significant difference (P < 0.05) compared to model group. The following table is the same.
Effect of lactobacillus paracasei L9 on intestinal motility in mice:
there are 3 modes of small intestine movement, namely tension contraction, segmental movement and peristalsis, and the main mode is that the peristalsis force pushes the intestinal contents to move. The compound diphenoxylate compound as the antidiarrheal agent for mice through oral gavage is a common medicine for constipation model modeling, and has the effects of mainly directly acting on intestinal smooth muscle, eliminating local intestinal mucosa peristalsis reflection to slow down intestinal tract peristalsis by inhibiting intestinal mucosa receptors, and delaying intestinal contents to cause difficulty in defecation of mice, which is similar to the clinical symptoms of constipation. After a mouse small intestinal peristalsis inhibition model is established through gastric perfusion, the influence of lactobacillus paracasei thalli on intestinal peristalsis of constipated mice is observed through ink marking. Experimental mice were continuously gavaged with skim milk containing L9 cells of Lactobacillus paracasei for 15 days, and then subjected to small intestine propulsion experiments, and the small intestine ink propulsion rates of the mice in each group are shown in Table 3.
TABLE 3 Effect of the test strains on the rate of propulsion of Constipation mouse intestinal ink
As can be seen from Table 3, the ink propelling rate of the model group is significantly lower than that of the blank group (P is less than 0.01), and the ink propelling experiment mice successfully model constipation models. After the gavage for 15 days, the intestinal ink propulsion rate of mice in each dose group of lactobacillus paracasei L9 is remarkably higher than that in the model group (P is less than 0.01). And the dosage effect is shown, and the intestinal peristalsis effect of constipation mice is strengthened along with the increase of the gavage dosage.
Claims (3)
1. The application of the lactobacillus paracasei L9 in preparing medicines, animal feeds or pet foods for treating or preventing constipation is characterized in that the lactobacillus paracasei L9 is preserved in the China general microbiological culture Collection center in 2014 in 10 months and 22 days with the preservation number of CGMCC NO.9800;
the lactobacillus paracasei L9 is a killed bacterium;
the edible object of the animal feed or the pet food is a cultured animal.
2. The veterinary drug is characterized by comprising lactobacillus paracasei L9, the lactobacillus paracasei L9 is preserved in China general microbiological culture collection center in 22 months and 10 months in 2014 with the preservation number of CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 10 3 -10 5 CFU/g; the lactobacillus paracasei L9 is inactivated bacteria.
3. The animal feed or pet food is characterized in that the animal feed or pet food contains lactobacillus paracasei L9, the lactobacillus paracasei L9 is preserved in the China general microbiological culture collection center in 2014 at 10 months and 22 days, the preservation number is CGMCC NO.9800, and the bacterial content of the lactobacillus paracasei L9 is 10 2 -10 4 CFU/g; the lactobacillus paracasei L9 is a killed bacterium.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910483931.4A CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910483931.4A CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110205270A CN110205270A (en) | 2019-09-06 |
| CN110205270B true CN110205270B (en) | 2023-02-10 |
Family
ID=67790805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910483931.4A Active CN110205270B (en) | 2019-06-05 | 2019-06-05 | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110205270B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110903995B (en) * | 2019-09-30 | 2023-03-24 | 内蒙古伊利实业集团股份有限公司 | Probiotic edible composition and food with digestion promoting effect |
| CN112694989A (en) * | 2020-12-21 | 2021-04-23 | 中国海洋大学 | Lactobacillus paracasei X11 and composition thereof constipation composite preparation and dairy product |
| CN115245198A (en) * | 2021-06-25 | 2022-10-28 | 丰宁水星乳品有限责任公司 | Almond powder product capable of relieving functional constipation |
| CN114651984A (en) * | 2022-03-30 | 2022-06-24 | 微康益生菌(苏州)股份有限公司 | Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation |
| CN115998777B (en) * | 2022-10-18 | 2023-11-17 | 汤臣倍健股份有限公司 | Use of lactobacillus paracasei 207-27 |
| CN116162570B (en) * | 2023-01-31 | 2023-10-17 | 东北农业大学 | Probiotic composition and preparation method and application thereof |
| CN116549494B (en) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN118272261B (en) * | 2024-03-28 | 2024-09-10 | 北京和益源生物技术有限公司 | Composite probiotic bacterial agent and application thereof in preparation of pet cat food |
| CN117987330B (en) * | 2024-04-03 | 2024-07-05 | 潍坊君薇生物科技有限责任公司 | Preparation method and application of lactobacillus paracasei GF027 freeze-dried powder with free radical removal and constipation relief effects |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523762A (en) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | Application of lactobacillus paracasei having antiallergic effect, functional food composition and preparation method of functional food composition |
| CN104560784A (en) * | 2014-12-10 | 2015-04-29 | 中国农业大学 | Lactobacillus paracasei and application thereof, fermentation product and preparation method thereof |
-
2019
- 2019-06-05 CN CN201910483931.4A patent/CN110205270B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523762A (en) * | 2014-12-10 | 2015-04-22 | 中国农业大学 | Application of lactobacillus paracasei having antiallergic effect, functional food composition and preparation method of functional food composition |
| CN104560784A (en) * | 2014-12-10 | 2015-04-29 | 中国农业大学 | Lactobacillus paracasei and application thereof, fermentation product and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 副干酪乳杆菌L9安全性评价;宋静颐等;《中国奶牛》;20151110(第21期);第27-31页 * |
| 含乳益生菌杏仁粉对便秘小鼠的通便作用;李桂花等;《中国奶牛》;20181115(第11期);第5页右栏第1段、第8页右栏第1段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110205270A (en) | 2019-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110205270B (en) | Application of lactobacillus paracasei L9 for relieving constipation of cultured animals | |
| CN112175864B (en) | Bifidobacterium animalis and breeding method and application thereof | |
| CN114774313B (en) | Use of lactobacillus rhamnosus LRa05 in preparing constipation relieving product or intestinal flora regulating product | |
| CN111826299B (en) | Bifidobacterium lactis for relaxing bowel and application and preparation thereof | |
| CN114146101B (en) | Application of bifidobacterium animalis subspecies lactis BLa80 in preparation of medicines or foods for regulating intestinal motility | |
| CN113855712B (en) | Composition capable of promoting defecation and application thereof | |
| CN105685970A (en) | Compound nutritious food capable of improving whole digestive tract | |
| CN110317761A (en) | A kind of bifidobacterium lactis and its application | |
| CN110882280A (en) | New application of lactobacillus paracasei K56 | |
| CN114681493B (en) | Application of bifidobacterium animalis subspecies lactis | |
| CN110892989A (en) | Lactobacillus paracasei ET-22 with function of relieving constipation | |
| CN110893193A (en) | Novel application of bifidobacterium lactis BL-99 | |
| CN115838675B (en) | Lactobacillus rhamnosus and composition and application thereof | |
| US20130309212A1 (en) | Lactobacillus salivarius and method for preparing metabolite thereof, composition of lactobacillus salivarius and metabolite thereof and use of the composition | |
| CN104415061A (en) | Edible composition as well as preparation method and application thereof | |
| CN116622587B (en) | Probiotic prepared by synthetic biological method, composition and application thereof | |
| CN107752015A (en) | The composite nutrient food that a kind of all-digestive tract improves | |
| CN111528486A (en) | Composition containing lactoferrin | |
| US20240316131A1 (en) | Physiologically acceptable yeast compositions and uses thereof | |
| CN115960784A (en) | Lactobacillus plantarum ZJUF SYS1 and application thereof | |
| CN110892961B (en) | Solid beverage containing bifidobacterium lactis BL-99 and application thereof | |
| CN113186118A (en) | Composite probiotic preparation for improving production performance of sows and preparation method thereof | |
| CN113355253B (en) | Bifidobacterium animalis and application thereof | |
| CN114145460A (en) | Lactic acid bacteria, composition containing same and application | |
| CN109549957A (en) | The compound probiotic of energy bidirectional modulation constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |